Meeting Coverage

IKCS

Thirteen-month survival gain falls short of statistical significance in observational study

Numerical advantage in median survival, response rate, durability with dendritic-cell agent

November 9, 2022

Nivolumab/ipilimumab achieves 1-year PFS of 100% in unresectable T1N0M0 tumors

November 7, 2022

Dramatic slowing of disease progression, prolonged responses with microbiome modulator

November 6, 2022

Present in roughly 5% of patients, survival worse in patients with larger or more lesions

November 18, 2019

Social media platform may be useful for trial recruitment, researchers say

November 5, 2017